PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report) VP Mark Elliott Boulding sold 15,521 shares of the company’s stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $53.30, for a total transaction of $827,269.30. Following the transaction, the vice president now owns 103,901 shares in the company, valued at $5,537,923.30. The trade was a 13.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
Mark Elliott Boulding also recently made the following trade(s):
- On Wednesday, February 19th, Mark Elliott Boulding sold 1,333 shares of PTC Therapeutics stock. The shares were sold at an average price of $50.10, for a total value of $66,783.30.
- On Tuesday, January 7th, Mark Elliott Boulding sold 1,543 shares of PTC Therapeutics stock. The stock was sold at an average price of $45.34, for a total value of $69,959.62.
PTC Therapeutics Price Performance
Shares of PTCT stock opened at $54.50 on Friday. The company has a market cap of $4.30 billion, a P/E ratio of -9.18 and a beta of 0.66. The stock’s 50-day moving average is $48.60 and its 200 day moving average is $43.51. PTC Therapeutics, Inc. has a 1-year low of $24.00 and a 1-year high of $55.65.
Institutional Inflows and Outflows
Wall Street Analyst Weigh In
Several equities analysts have commented on the company. Scotiabank started coverage on PTC Therapeutics in a research report on Friday, March 7th. They issued a “sector perform” rating and a $55.00 price objective on the stock. Barclays raised their price target on shares of PTC Therapeutics from $45.00 to $56.00 and gave the stock an “equal weight” rating in a research note on Tuesday, December 3rd. Wells Fargo & Company lifted their price objective on shares of PTC Therapeutics from $56.00 to $68.00 and gave the company an “overweight” rating in a report on Tuesday, November 26th. UBS Group upped their target price on shares of PTC Therapeutics from $47.00 to $71.00 and gave the stock a “buy” rating in a research note on Tuesday, December 3rd. Finally, JPMorgan Chase & Co. lifted their price target on shares of PTC Therapeutics from $72.00 to $78.00 and gave the company an “overweight” rating in a research note on Friday. Two investment analysts have rated the stock with a sell rating, five have given a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $64.00.
View Our Latest Stock Report on PTC Therapeutics
PTC Therapeutics Company Profile
PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.
Featured Stories
- Five stocks we like better than PTC Therapeutics
- What is a Stock Market Index and How Do You Use Them?
- Rubrik Stock’s V-Bottom Reversal Signals a Major Rally Ahead
- Are Penny Stocks a Good Fit for Your Portfolio?
- How Super Micro Computer Stock Is Defying the Market Sell-Off
- Golden Cross Stocks: Pattern, Examples and Charts
- AppLovin vs. HPE: Which Tech Stock Can Bounce Back Faster?
Receive News & Ratings for PTC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.